Alprostadil (ICI Therapy)
A second-line, highly effective local vasodilatory agent injected directly into the corpus cavernosum for targeted Erectile Dysfunction (ED) management.
Clinical Highlights
- Independent Mechanism: Works directly via EP receptor activation, bypassing the Nitric Oxide pathway required by oral PDE5 inhibitors.
- Second-Line Efficacy: Proven gold-standard therapy for patients unresponsive to or contraindicated for oral ED medications.
- Specialist Protocol: Requires initial in-clinic dose titration and auto-injector technique instruction by a urologist.
What is Intracavernosal Injection (ICI)?
Understanding the local pharmacodynamics of Alprostadil (Prostaglandin E1) and its definitive role in managing Refractory Erectile Dysfunction under urologist expert care.
Direct Vascular Mechanism: Bypassing Nervous System & Libido
Unlike oral PDE5 inhibitors (such as Sildenafil or Tadalafil) which rely strictly on intact cavernous nerves, sexual arousal, and psychogenic libido to generate Nitric Oxide (NO), Alprostadil Intracavernosal Injection (ICI) operates completely independently of the neurological and psychological pathways. It acts directly as a localized, potent smooth muscle relaxant within the erectile tissue.
EP Receptor Activation
Alprostadil binds directly to PGE1 (EP) receptors on cavernous smooth muscle cells, bypassing neurovascular transmission and intact cavernous nerve signaling.
Intracellular cAMP Elevation
Triggers adenylate cyclase activation, raising cyclic AMP (cAMP) levels and decreasing intracellular free calcium, forcing rapid, predictable vascular smooth muscle relaxation.
Veno-Occlusion & Erection
Rapid arterial dilation surges cavernous blood flow, compressing subtunical venules to trap blood locally—producing a full erection in 5–15 minutes without requiring sexual desire or libido.
Gold-Standard Clinical Practice Guidelines
American Urological Association
The AUA strongly recommends Intracavernosal Injection (ICI) as an effective, second-line treatment for men with Refractory Erectile Dysfunction who fail or cannot tolerate oral therapies. AUA emphasizes that proper in-clinic dose titration under a urologist expert maximizes efficacy while minimizing risks like priapism.
European Association of Urology
EAU guidelines endorse Alprostadil ICI for severe vasculogenic, neurogenic, or post-radical prostatectomy ED. EAU highlights its high success rate (over 70–85%) and notes its clinical superiority in restoring rigid erections when cavernous nerve injury prevents oral PDE5 inhibitor responsiveness.
Campbell-Walsh-Wein Urology
Considered the global benchmark in urological surgery, Campbell-Walsh highlights ICI as the most reliable non-surgical therapeutic option for organic ED. By directly inducing corporal vasodilation, it provides immediate diagnostic and therapeutic utility for complex vasculogenic or post-surgical cases.
Specialized Dose Titration & Administration
Strict urological supervision, personalized dose titration, and mandatory hands-on injection training to ensure maximum efficacy and absolute patient safety.
Initial Urologist-Led Office Titration
Alprostadil Intracavernosal Injection (ICI) requires individualized dose determination to prevent adverse events such as priapism or local tissue discomfort.
- Starting Dose: Typically initiated at 2.5 mcg to 5.0 mcg in the clinic under direct supervision of our urologist expert.
- Dose Escort & Monitoring: Incremental titrations (by 2.5 mcg to 5.0 mcg increments) are performed until a firm erection lasting 30 to 60 minutes is achieved.
- Maximum Dose: Maximum single dose should not exceed 40 mcg according to AUA and EAU clinical guidelines.
Mandatory In-Clinic Hands-On Training & Cold-Chain Policy
Physician-Led Step-by-Step Training
To guarantee patient safety and confidence, our urologist performs a detailed, step-by-step demonstration and guides the patient through hands-on practice in the clinic. Medication will only be dispensed once the urologist confirms the patient has mastered proper anatomical placement (lateral corpus cavernosum), sterile technique, and micro-needle injection depth.
Mandatory Cold Thermal Bag Requirement
Alprostadil is a temperature-sensitive biological PGE1 compound requiring strict cold-chain preservation (2°C–8°C). Patients are strictly required to bring a thermal insulated bag with ice packs when receiving their prescription to preserve drug potency and maintain optimal stability during transport.
Home Self-Administration & Frequency Protocol
Strictly limited to a maximum of 1 injection per 24 hours, and no more than 3 times per week, with at least 24 hours between doses.
Alternate injection sites between the left and right sides of the penile shaft (10 or 2 o'clock positions) to prevent localized tissue fibrosis or nodule formation.
Utilize sterile micro-fine needles (27G–30G) and discard immediately after a single use into a designated biohazard needle container.
Indications, Contraindications & Precautions
Comprehensive clinical safety parameters, risk factors, and mandatory emergency protocols for Alprostadil Intracavernosal Injection (ICI) therapy.
Clinical Indications
- Refractory Erectile Dysfunction: Patients unresponsive to or intolerant of oral PDE5 inhibitors (Sildenafil, Tadalafil).
- Neurogenic ED: Secondary to spinal cord injury, radical prostatectomy, or pelvic surgery (bypassing damaged nerve pathways).
- Vasculogenic & Organic ED: Severe arterial insufficiency or corporal veno-occlusive dysfunction.
- Diagnostic Evaluation: Diagnostic intracavernosal testing to assess penile vascular response during urological workups.
Contraindications
- Conditions Predisposing to Priapism: Sickle cell anemia/trait, multiple myeloma, or leukemia.
- Anatomical Deformities: Severe Peyronie’s disease, angulation, cavernosal fibrosis, or penile implants.
- Hypersensitivity: Known allergy to Alprostadil (PGE1) or any component of the formulation.
- Unsuited for Sexual Activity: Men for whom sexual intercourse is inadvisable due to unstable cardiovascular conditions.
Clinical Precautions & Symptoms to Monitor
Penile Pain & Local Reaction
Mild to moderate transient burning or dull ache during or after injection occurs in 10-20% of patients due to PGE1 receptor sensitivity. Report persistent pain to your urologist.
Cavernosal Fibrosis & Plaques
Long-term use requires periodic urological palpation of the penile shaft to detect fibrotic nodules or plaque development. Site rotation minimizes this risk.
Hematoma & Ecchymosis
Bleeding or bruising at the injection site can occur if a superficial vein is punctured. Apply firm pressure to the site for 3–5 minutes immediately post-injection.
Priapism Warning: Prolonged Erection > 4 Hours
Priapism (a prolonged erection lasting more than 4 hours) is a severe medical emergency. Uncontrolled prolonged erection causes irreversible ischemic injury, corporal tissue necrosis, and permanent erectile failure.
On-Demand PDE5i vs. Daily Tadalafil vs. Alprostadil (ICI) vs. Li-ESWT
A comprehensive comparative guide analyzing first-line oral regimens, continuous micro-dosing, second-line intracavernosal therapy, and regenerative shockwave technology.
| Clinical Parameter | On-Demand PDE5i Sildenafil / Tadalafil | Daily Tadalafil Tadalafil 2.5mg - 5mg Daily | Alprostadil (ICI) Intracavernosal Injection | Li-ESWT Shockwave Therapy |
|---|---|---|---|---|
| Primary Indication | Mild-to-Moderate ED (Episodic / Scheduled) | Mild-to-Moderate ED + Lower Urinary Tract Symptoms (LUTS/BPH) | Refractory ED / Severe Organic ED (Post-Prostatectomy) | Mild-to-Moderate Vasculogenic ED (Regenerative Intent) |
| Mechanism & Pathway | Inhibits PDE5; relies on NO-cGMP surge post-arousal | Sustained steady-state PDE5 inhibition & endothelial optimization | Direct PGE1 (cAMP) smooth muscle relaxation | Acoustic micro-trauma triggering VEGF release & angiogenesis |
| Nerve & Libido Dependency | Required (Intact nerves & arousal essential) | Required (Requires intact reflex arc & sexual desire) | Independent (Bypasses cavernous nerve damage & libido) | Indirect (Restores vascular substrate for arousal response) |
| Onset & Spontaneity | 30–60 min onset; planned intimacy window | Steady-state after 3–5 days; 100% spontaneous intimacy | Rapid 5–15 min onset; highly predictable erection | Cumulative improvement over 6–12 treatment sessions |
| Efficacy in Refractory ED | Low in severe nerve/vascular damage | Moderate (Improves endothelial health over time) | Gold Standard (70%–85% success in PDE5i failures) | Variable (Best as monotherapy in mild ED or combo with PDE5i) |
| Key Safety / Contraindications | Nitrate contraindication; facial flushing, headache | Nitrate contraindication; low incidence of myalgia/dyspepsia | Sickle cell, leukemia, priapism risk; requires cold thermal bag | Local malignancy or active severe bleeding disorders |
On-Demand PDE5i (Sildenafil / Tadalafil)
Best for patients with intact neurovascular supply who prefer taking medication prior to planned sexual activity. Requires active sexual stimulation and intact libido to trigger erection.
Daily Tadalafil (5mg Once-Daily)
Provides continuous therapeutic blood levels, restoring complete sexual spontaneity without scheduling doses around meals or intimacy. Simultaneously improves lower urinary tract symptoms (LUTS/BPH).
Alprostadil Intracavernosal Injection (ICI)
The definitive urological intervention for severe ED when oral medications fail. By bypassing damaged cavernous nerves and psychogenic libido requirements, it delivers rapid, consistent, rigid erections.
Low-Intensity Shockwave Therapy (Li-ESWT)
A non-invasive, drug-free therapeutic approach that stimulates neovascularization within the cavernous tissue. Designed to restore physiological erectile function rather than managing symptoms temporarily.
Why Choose ASY Men’s Health?
We combine specialized urological expertise, evidence-based treatment protocols, and utmost discretion to deliver personalized erectile restoration plans.
Board-Certified Urological Care
Your diagnosis and treatment protocol are designed by experienced medical specialists trained in male sexual dysfunction, ensuring safe, individualized, and effective medical care.
Comprehensive ED Spectrum
We offer the complete range of clinical solutions—from first-line oral PDE5i (Sildenafil/Tadalafil) and restorative Li-ESWT to second-line Alprostadil ICI—ensuring options for all severity levels.
100% Discreet & Confidential
We respect your privacy. All consultations, clinical records, and home delivery services are handled under strict medical confidentiality with unbranded, discreet packaging.
Guaranteed Authentic Medications
All pharmaceutical therapies (PDE5i, Alprostadil) are sourced directly from certified manufacturers and stored under strict temperature-controlled cold-chain management.
Guided Hands-on Instruction
For second-line therapies like Alprostadil (ICI), our clinicians provide step-by-step in-clinic training and dosing titration to guarantee maximum safety, comfort, and confidence at home.
Ongoing Clinical Monitoring
Erectile recovery is a continuous process. We track your therapeutic response over time, adjusting dosages or combining therapies (e.g., Shockwave + PDE5i) for optimal long-term health.
Frequently Asked Questions
Expert medical answers to common questions regarding oral PDE5 inhibitors, intracavernosal injections, and shockwave therapy.
What should I do if oral PDE5i (Sildenafil or Tadalafil) stops working or fails?
Up to 30–40% of non-responders can achieve success by addressing common usage errors: ensuring full sexual stimulation, taking Sildenafil on an empty stomach, or allowing at least 4–8 separate trial doses before declaring treatment failure. If oral therapy remains ineffective, consult a urologist to evaluate second-line treatments such as Alprostadil Intracavernosal Injection (ICI), which bypasses damaged nerve pathways entirely, or Low-Intensity Shockwave Therapy (Li-ESWT) to restore underlying microvasculature.
Can I combine oral medications (PDE5i) with Low-Intensity Shockwave Therapy (Li-ESWT)?
Yes, absolute synergy exists. Clinical guidelines from the EAU support combining Li-ESWT with oral PDE5i therapy. Shockwave therapy works restoratively by inducing neovascularization (new blood vessel growth) and microvascular repair over several weeks, while PDE5 inhibitors provide immediate vasodilation during sexual activity. Many non-responders to oral PDE5i regain responsiveness after completing a standard course of Li-ESWT.
Is Intracavernosal Injection (ICI) with Alprostadil painful or difficult to self-administer?
Most patients report minimal discomfort because ICI uses ultra-fine needles (30-gauge) placed into the lateral shaft of the penis, where pain receptors are scarce. During your initial in-clinic visit, our urological team performs guided titration and hands-on injection training. Once trained, self-administration takes less than a minute at home and provides highly predictable erections within 5 to 15 minutes.
What is Priapism, and what should I do if my erection lasts too long?
Priapism is a prolonged, often painful erection lasting longer than 4 hours without sexual stimulation. It is a rare side effect associated primarily with injectable therapies (Alprostadil) and high-dose oral medications. Priapism is a medical emergency. If an erection persists beyond 4 hours, seek immediate urological or emergency care to receive pharmacological reversal (e.g., intracavernosal phenylephrine) to prevent permanent tissue fibrosis.
Are there any absolute contraindications for taking ED medications with heart conditions?
Concomitant nitrate therapy is an absolute contraindication. Oral PDE5 inhibitors (Sildenafil and Tadalafil) must never be taken alongside nitrate medications (e.g., Nitroglycerin, Isosorbide mononitrate/dinitrate, or recreational "poppers"), as this combination can induce severe, life-threatening hypotension. For patients requiring organic nitrates for angina, non-systemic options such as Alprostadil ICI or non-pharmacological Li-ESWT are safer, alternative medical choices under urological supervision.
Clinical References & Evidence Literature
- American Urological Association (AUA). (2018; Amended 2024). Erectile Dysfunction: AUA Guideline. Journal of Urology. Evaluation and management of erectile dysfunction including PDE5 inhibitors, intracavernosal injections, and restorative therapies.
- European Association of Urology (EAU). (2024). EAU Guidelines on Sexual and Reproductive Health. EAU Guidelines Office, Arnhem, The Netherlands. First-line pharmacotherapy, penile injection protocols, and Low-Intensity Shockwave Therapy (Li-ESWT) recommendations.
- Burnett, A. L., et al. (2018). Erectile Dysfunction: AUA Guideline. The Journal of Urology, 200(3), 633–641. Comprehensive breakdown of treatment algorithms and non-responder troubleshooting.
- Gruenwald, I., Appel, B., & Vardi, Y. (2013). Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. The Journal of Sexual Medicine, 10(1), 222–231.
- Partin, A. W., Dmochowski, R. R., Kavoussi, L. R., & Peters, C. A. (2020). Campbell-Walsh-Wein Urology (12th ed.). Elsevier. Chapter on Physiology of Penile Erection and Pathophysiology of Erectile Dysfunction.